Niedźwiedzi
HSBC downgrades Pfizer (PFE) to 'Hold' with $28 target amid pipeline concerns.
Ten briefing nie jest jeszcze dostępny w tym języku — wyświetlana jest wersja angielska.
HSBC has downgraded Pfizer's stock rating to 'Hold' from 'Buy' and reduced the price target to $28, citing diminished confidence in the company's short-term growth prospects. This decision follows a 40% probability adjustment for the market introduction of sigvotatug vedotin after a Phase 3 trial failure in non-small cell lung cancer. Additionally, HSBC increased the beta coefficient to 0.85 from 0.78, indicating higher expected volatility.
Kluczowe punkty
- HSBC downgrades Pfizer's stock rating to 'Hold' and lowers price target to $28.
- Reduced confidence in sigvotatug vedotin's market introduction after Phase 3 trial failure.
- Beta coefficient raised to 0.85, suggesting increased stock volatility.
Źródła
Wygenerowane przez AI na podstawie publicznych źródeł wiadomości. To nie jest porada finansowa.
